CAPA & Quality Systems

CAPA, deviations, OOS, change control, validation and quality metrics: how quality systems are meant to work and where FDA finds them failing.

21 CFR 211.192 cover: 296 drug Form 483s cited weak investigations, with 41.2% of those inspections ending OAI against 18.8% without the citation.

21 CFR 211.192: production record review, what FDA cites, and what an investigation file needs

What 21 CFR 211.192 requires (quality unit review of production records before release, and a thorough, written investigation of any unexplained discrepancy that extends to other batches), what counts as an unexplained discrepancy, how FDA words 211.192 observations on Form 483s, which firms drew the citation in 2025 and 2026, how it relates to OAI outcomes, and what a defensible investigation file contains, from 302 observations on 296 drug inspections that closed January 2025 to October 2026.

Cleaning validation FDA and EMA requirements, with 21 CFR 211.67 citation data

CAPA & Quality Systems

Cleaning validation: FDA and EMA requirements, acceptance limits, and what 483s cite

What FDA and EMA require for cleaning validation: 21 CFR 211.67 and 211.182, FDA's 1993 inspection guide, ICH Q7 section 12.7, EU GMP Annex 15 and the EMA guideline on health-based exposure limits. Covers acceptance limits (HBEL/PDE, 1/1000 dose, 10 ppm), protocols, sampling, hold times and continued verification, with Atlas data on how often 211.67 appears on 2025 and 2026 human drug Form 483s.

FDA Quality Metrics Program

Atlas

CAPA & Quality Systems

The FDA quality metrics program in 2026: practice areas, QMM, and what Form 483s measure

What the FDA quality metrics program is, why reporting is still not required, the four practice areas FDA proposed in 2022 with their example metrics, how the program differs from CDER's voluntary Quality Management Maturity assessments, and which 21 CFR Part 211 sections FDA investigators cited in each practice area across 779 human drug Form 483s issued from January 2025 to July 2026.

Continued process verification guide cover: drug Form 483s citing 21 CFR 211.110(a) average 7.9 observations

CAPA & Quality Systems

Continued Process Verification (CPV): FDA Requirements, Metrics and a Review Checklist

Continued process verification is the ongoing monitoring that shows a validated commercial process stays in a state of control. This guide covers the FDA requirements behind CPV, how often drug 483s cite process monitoring, the metrics worth trending, review frequency, escalation rules, what two 2026 warning letters asked for, and a review checklist.

CAPA & Quality Systems

ICH Q9 quality risk management: what Q9(R1) requires in practice

ICH Q9 sets the principles for quality risk management (QRM) across the drug product lifecycle. This guide explains what the 2023 Q9(R1) revision changed, walks through the QRM process and formality tiers, shows how to link QRM to CAPA, change control and supplier oversight, and uses Atlas Form 483 data to show where weak risk management becomes a citation.

Weak CAPA Investigation Systems.

Atlas

CAPA & Quality Systems

Why do so many companies receive citations for weak CAPA and investigation systems?

Weak CAPA and investigation systems drive a high share of Form 483s and warning letters. This guide breaks down why investigations stop at "human error," how regulators read CAPA records, and the specific procedure, RCA, and governance fixes that make the system audit-ready.

CAPA Effectiveness Checks and Metrics

Atlas

CAPA & Quality Systems

CAPA Effectiveness Checks and Metrics: How to Prove a Fix Worked

A CAPA effectiveness check proves that the problem behind a CAPA did not come back. This guide separates effectiveness from verification, sets out the four fields every check needs, compares the methods that produce real evidence, explains sample size and confidence, scales rigor to risk, lists the program-level CAPA effectiveness metrics, and shows what FDA cites when effectiveness is missing, using Atlas Form 483 data and two warning letters. A copyable planning template is included.

Nonconformance: Types, NCR and Prevention

Atlas

CAPA & Quality Systems

What Is a Nonconformance? Types, the NCR, and How FDA Cites It

A nonconformance (also written non-conformance or nonconformity) is any failure to meet a specified requirement. This guide covers the ISO 9000 definition, the critical, major and minor types with GMP examples, the fields of a nonconformance report (NCR), the disposition workflow from segregation to CAPA, how a nonconformance differs from a deviation, an OOS result and a CAPA, the regulations that govern it (ISO 13485 clause 8.3 under the QMSR, 21 CFR 211.192, 211.115 and 211.165(f)), and how often FDA cited these sections on 2026 Form 483s.

OOS Meaning: Out of Specification

Atlas

CAPA & Quality Systems

OOS Meaning in Pharma: Out of Specification Results, OOS vs OOT, and the FDA Investigation

OOS stands for Out of Specification, a test result that falls outside the approved acceptance criteria. This guide explains the OOS meaning in pharma, how it differs from OOT, the phase I laboratory and phase II full-scale investigation in FDA's OOS guidance, the rules on retesting, resampling and averaging, and how often FDA cites 21 CFR 211.192 and 211.160 in drug inspections, with named 2025 and 2026 Form 483 examples.

Quality Control Methods in Pharma.

Atlas

CAPA & Quality Systems

Quality Control Methods in Pharma: Definitions and Practical Use

Discover what quality control is and the essential methods used. Learn about inspection, SPC, and tools like Pareto charts.

Corrective Action Requests.

Atlas

CAPA & Quality Systems

What Is a Corrective Action Request (CAR)? Process, Form and ISO Rules

A corrective action request (CAR) is the internal document that assigns a nonconformity to an owner, who must find the root cause, fix it and prove the fix works. This guide covers when a CAR is raised, the CAR workflow step by step, what a CAR form contains, CAR vs SCAR vs CAPA, what ISO 9001 clause 10.2 and ISO 13485 clause 8.5.2 require, the metrics that show whether a CAR system works, and what 2026 FDA Form 483s cite when it does not.

Pharma Change Control Under Review.

Atlas

CAPA & Quality Systems

Pharma Change Control: 21 CFR 211.100 and 820.70

Change control is how regulated teams manage project modifications without breaking compliance. This guide covers the four types of change control, a six-step process, and a pharma manufacturing example showing it in action.

QA Compliance Metrics That Matter.

Atlas

CAPA & Quality Systems

What metrics should QA teams track for compliance success?

Quality Assurance (QA) teams are the silent guardians of compliance in regulated industries. Yet, many organizations overlook the key metrics that reflect...

CAPA Guide 2026

Atlas

CAPA & Quality Systems

CAPA in Pharma and Medical Devices: Corrective and Preventive Action Guide (2026)

CAPA stands for Corrective and Preventive Action: the quality system process that finds the cause of a problem, removes it, and proves it will not recur. This guide covers the definition, corrective vs preventive action, the process step by step, root cause tools, effectiveness checks, the drug and device requirements (21 CFR 211.192, 211.22 and ISO 13485 under QMSR), supplier CAPA, and what FDA cites most, using Atlas inspection data.